Deneysel Bir Çalışma: Multivitaminler Takrolimus Düzeyinin, Parasetamol ve Trimetoprim Sülfametoksazol ise Siklosporin Düzeyinin Düşük Ölçülmesine Neden Oluyor

Öz

İlaç-ilaç etkileşiminin aksine ilaç-kit etkileşimi birçok hekimin gözden kaçırdığı bir durumdur. Nakilden sonra immunsupresyon etkileri nedeniyle yaşam boyu kullanılan takrolimus, siklosporin gibi ilaçların etkinliği ve güvenliği büyük ölçüde plazma konsantrasyonlarına bağlı olup, doz ayarlaması kritik öneme sahiptir. Nakil sonrası dönemde kullanılan diğer ilaçlarla olan etkileşimler, takrolimus ve siklosporin ölçüm sonuçlarını değiştirebilir, tedavide yanlış doz ayarlamalarına yol açabilir. Çalışmada ilaçların takrolimus ve siklosporin ölçüm sonuçları üzerindeki etkilerini incelemek için16 farklı ilaç solüsyonu kullanıldı. Hazırlanan numuneler biyokimya analizöründe çalışıldı. Tüm ölçümler 20 kez tekrarlandı ve ortalama değerleri alındı. Elde edilen sonuçların hedef değerden ne oranda saptığını hesaplamak için bias (%) formülü kullanıldı. Takrolimus ölçümlerinde parasetamol dışındaki ilaçların oluşturduğu interferans anlamlı olarak saptandı (p<0,001). Multivitamin, en fazla sapmaya neden olan ilaçtı. Siklosporin konsantrasyonunda en fazla sapma trimetoprim sülfametoksazol ve parasetamol ile oldu. Siklosporinin, diğer ilaçların varlığında takrolimusa göre daha fazla ölçüm hatasına maruz kaldığı bulundu. Hastaların ve kan ilaç düzeylerinin sıkı takibi tedavinin güvenliğini artırmada kritik öneme sahiptir. Klinisyenin test sonuçlarını değerlendirirken immun assay yöntemlerin daha fazla farkında olması, çalışmalarla etkileşimleri gösterilmiş ilaçların laboratuvar sonucunu değerlendirirken güncel literatürü dikkate alarak yaklaşımı önemlidir.

Anahtar Kelimeler

• Organ nakli
• immunsüpresif ilaçlar
• ilaç-ilaç etkileşimi

An Experimental Study: Multivitamins Cause Low Tacrolimus Levels, Paracetamol and Trimethoprim Sulfamethoxazole Cause Low Cyclosporine Levels

Öz

Unlike drug-drug interactions, drug-kit interactions are a situation that many physicians overlook. The efficacy and safety of drugs such as tacrolimus and cyclosporine, which are used throughout life due to their immunosuppressive effects after transplantation, largely depend on plasma concentrations, and dose adjustment is of critical importance. Interactions with other drugs used in the post-transplant period can change the tacrolimus and cyclosporine measurement results and lead to incorrect dose adjustments in treatment. In the study, 16 different drug solutions were used to examine the effects of various drugs on the measurement results of tacrolimus and cyclosporine. The prepared samples were studied in the biochemistry analyzer. All measurements were repeated 20 times, and their average values were taken. The bias (%) formula was used to calculate the extent to which the obtained results deviated from the target value. In tacrolimus measurements, the interference caused by drugs other than paracetamol was significantly detected (p<0.001). Multivitamin was the drug that caused the most deviation. The highest deviation in cyclosporine concentration was with trimethoprim, sulfamethoxazole, and paracetamol. Cyclosporine was found to be subject to more measurement error than tacrolimus in the presence of other drugs. Close monitoring of patients and blood drug levels is critical to increasing the safety of treatment. It is essential for clinicians to be more aware of immunoassay methods when evaluating test results and to consider current literature when assessing laboratory results of drugs that have been shown to interact in studies.

Anahtar Kelimeler

• Transplantation
• immunosuppression
• drug-drug interactions

Kaynakça

1. 1.Ciftci HS, Ayna TK, Calıskan Y, Guney I, Gurtekin M.Pharmacogenetics and Calcineurin Inhibitors. Türkiye Clinics J Nephrol. 2011;6(2):62-8.
2. 2.Halloran PF. Immunosuppressive drugs for kidneytransplantation. N Engl J Med. 2004 Dec 23;351(26):2715-29. doi: 10.1056/NEJMra033540. Erratum in: N Engl J Med. 2005Mar 10;352(10):1056. PMID: 15616206.
3. 3.Alpay N, Yıldız A. Long-Acting Tacrolimus Use in AdultKidney Transplant Patients, Effects on Long-Term Kidney andPatient Survival, Single Center Experience. Sakarya Med J2023 ;13(2):240-246 DOI: 10.31832/smj.1255312
4. 4.Hesselink DA, Bouamar R, Elens L, van Schaik RH, vanGelder T. The role of pharmacogenetics in the disposition ofand response to tacrolimus in solid organ transplantation. ClinPharmacokinet. 2014 Feb;53(2):123-39. doi: 10.1007/s40262-013-0120-3. PMID: 24249597.
5. 5.Christians U, Strom T, Zhang YL, et al. Active drug transportof immunosuppressants: new insights for pharmacokinetics andpharmacodynamics. Ther Drug Monit. 2006 Feb;28(1):39-44. doi: 10.1097/01.ftd.0000183385.27394.e7. PMID: 16418692.
6. 6.Oz O, Gonel A. Analytical Interference with Contrast Agents in Genetic Test Result for Thrombophilia. Letters in DrugDesign&Discovery.2024;21(4):823-7.
7. 7.Pehlivan VF, Gönel A, Pehlivan B, Koyuncu I. FalseLaboratory Test Result Through Colistin Interference in anIntensive Care Patient: Case Report. Comb Chem HighThroughput Screen. 2020;23(8):827-831. doi:10.2174/1386207323666200514072705. PMID: 32407261.
8. 8.Tayman MA, Gonel A. In Vitro Investigation of the Effect ofMouthwashes on Fertility Tests: Interference Effect ofMouthwashes. İJCMBS [Internet]. 2025 Jan. 3 [cited 2025 Mar. 10];5(1). Available from: https://ijcmbs.com/index.php/ijcmbs/article/view/176

9. 9.Tascanov MB, Gönel A. How Do Contrast Agents AffectCardiac Markers and Coagulation Tests? Experimental Study.Comb Chem High Throughput Screen. 2019 Aug 8;22(5):355-360.doi: 10.2174/1386207322666190603170438. PMID:31161978.
10. 10.Gönel A, Koyuncu I, Bayraktar N, et al. Enzyme ReplacementTherapy may Affect Blood Immunosuppressant Monitoring.Curr Pediatr Rev. 2020;16(4):314-319. doi:10.2174/1573396316666200507092858. PMID: 32379593.
11. 11.Gönel A, Koyuncu I. False Immunosuppressant Measurement by LC-MS/MS Method Due to Radiopaque Agents. CombChem High Throughput Screen. 2019;22(2):129-134. doi:10.2174/1386207322666190418125307. PMID: 31038053.
12. 12.James A, Stalan J, Kuzhively J. Biotin induced biochemicalhyperthyroidism: a case report and review of the literature. JMed Case Rep. 2023 Jun 28;17(1):266. doi: 10.1186/s13256-023-04002-z. PMID: 37370185; PMCID: PMC10304644.
13. 13.Haddad RA, Giacherio D, Barkan AL. Interpretation ofcommon endocrine laboratory tests: technical pitfalls, theirmechanisms and practical considerations. Clin Diabetes Endocrinol. 2019 Jul 24;5:12. doi: 10.1186/s40842-019-0086-7. PMID: 31367466; PMCID: PMC6657094.
14. 14.Kodani M, Poe A, Drobeniuc J, Mixson-Hayden T.Determination of potential biotin interference on accuracy ofresults of serologic assays for various viral hepatitis markers. JMed Virol. 2020 Dec;92(12):3875-3879. doi:10.1002/jmv.25880. Epub 2020 Apr 25. PMID: 32285946.
15. 15.Gönel A, Tascanov MB, Bayraktar N, et al. In VitroDemonstration of Drug-Reagent Interactions AmongCommonly Used Parenteral Drugs in Cardiology. CardiovascHematol Agents Med Chem. 2021;19(1):43-49. doi:10.2174/1871525718666200226115235. PMID: 32101135.
16. 16.Sauerland S, Nagelschmidt M, Mallmann P, Neugebauer EA.Risks and benefits of preoperative high dosemethylprednisolone in surgical patients: a systematic review.Drug Saf. 2000 Nov;23(5):449-61. doi: 10.2165/00002018-200023050-00007. PMID: 11085349.
17. 17.Available from: https://go.drugbank.com/drugs/DB00959 (Access date: 25.02.2025).
18. 18.Aberer F, Hochfellner DA, Sourij H, Mader JK. A PracticalGuide for the Management of Steroid Induced Hyperglycaemiain the Hospital. J Clin Med. 2021 May 16;10(10):2154. doi:10.3390/jcm10102154. PMID: 34065762; PMCID:PMC8157052.
19. 19.Gendron AA, Marquis A, Mongeon C, Statie A, Bouchard A,Khazaka M. Potassium Supplementation to Prevent SevereHypokalemia and Paralysis after High-DoseMethylprednisolone for Ophthalmopathy in UncontrolledGraves Disease: A Case Report. Can J Hosp Pharm. 2022 Jul4;75(3):231-233. doi: 10.4212/cjhp.3145. PMID: 35847458;PMCID: PMC9245406.
20. 20.Tamez-Pérez HE, Cisneros-Pérez V, Cedillo-Rodríguez JA, etal. Prevalence of hypokalemia in patients withmethylprednisolone pulse therapy. Rev Invest Clin.2009;61(3):194-197.
21. 21.Gutkowski K, Chwist A, Hartleb M. Liver injury induced byhigh-dose methylprednisolone therapy: a case report and briefreview of the literature. Hepat Mon. 2011 Aug;11(8):656-61. doi: 10.5812/kowsar.1735143x.713. PMID: 22140391;PMCID: PMC3227489.
22. 22.Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinalmucosal damage. Arthritis Res Ther. 2013;15 Suppl 3(Suppl3):S3. doi: 10.1186/ar4175. Epub 2013 Jul 24. PMID:24267289; PMCID: PMC3890944.
23. 23.Lanas A, García-Rodríguez LA, Arroyo MT, et al. Asociación Española de Gastroenterología. Risk of upper gastrointestinalulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006Dec;55(12):1731-8. doi: 10.1136/gut.2005.080754. Epub 2006May 10. PMID: 16687434; PMCID: PMC1856452.
24. 24.Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007 Jul;21(7):1387-94. doi: 10.1038/sj.leu.2404683. Epub 2007 Apr 5. PMID:17410187.
25. 25.Shenton BK, White MD, Bell AE, et al. The paradox of ATGmonitoring in renal transplantation. Transplant Proc. 1994Dec;26(6):3177-80. PMID: 7998108.
26. 26.Duftner C, Dejaco C, Hengster P, et al. Apoptotic effects ofantilymphocyte globulins on human pro-inflammatory CD4+CD28- T-cells. PLoS One. 2012;7(3):e33939. doi:10.1371/journal.pone.0033939. Epub 2012 Mar 30. PMID:22479483; PMCID: PMC3316508.
27. 27.Available from: https://www.drugs.com/drug-interactions/anti-thymocyte-globulin-rabbit.html. (Access date: 25.02.2025)
28. 28.Wheat LJ, Connolly P, Durkin M, et al. False-positive Histoplasma antigenemia caused by antithymocyte globulinantibodies. Transpl Infect Dis. 2004 Mar;6(1):23-7. doi:10.1111/j.1399-3062.2004.00045.x. PMID: 15225223.
29. 29.Kaur A, Eberlein M, Klesney-Tait J, Durkin MM, Wheat LJ,Gajurel K. Rabbit Antithymocyte Globulin Causes Blastomyces and Histoplasma Antigenemia. Open Forum Infect Dis. 2019 Mar 28;6(5):ofz165. doi: 10.1093/ofid/ofz165. PMID: 31065562; PMCID: PMC6499897.
30. 30.Dasgupta A. Immunoassay design and biotin interference. AdvClin Chem. 2022;109:165-183. doi:10.1016/bs.acc.2022.03.005. Epub 2022 May 5. PMID:35953126.
31. 31.Samarasinghe S, Meah F, Singh V, et al. Biotin InterferenceWith Routine Clinical Immunoassays: Understand The Causesand Mitigate The Risks. Endocr Pract. 2017 Aug;23(8):989-998.doi: 10.4158/EP171761.RA. Epub 2017 May 23. PMID:28534685.
32. 32.Li D, Ferguson A, Cervinski MA, Lynch KL, Kyle PB. AACCGuidance Document on Biotin Interference in Laboratory Tests. J Appl Lab Med. 2020 May 1;5(3):575-587. doi: 10.1093/jalm/jfz010. PMID: 32445355.
33. 33.Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetesmellitus after kidney transplantation in the United States. Am JTransplant. 2003 Feb;3(2):178-85. doi: 10.1034/j.1600-6143.2003.00010.x. PMID: 12603213.
34. 34.Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomesfrom BENEFIT, a randomized, active-controlled, parallel-groupstudy in adult kidney transplant recipients. Am J Transplant.2012 Jan;12(1):210-7. doi: 10.1111/j.1600-6143.2011.03785.x. Epub 2011 Oct 12. PMID: 21992533.